Surrozen, Inc./DE
Closed (deSPAC)Profile in progress
- What it is
- A private company preparing to list via a SPAC merger. Full profile in progress.
- What it’s doing now
- Merging with Consonance-HFW Acquisition Corp. (CHFW) — closed (despac).
- What you should know
- Data is still being assembled for this company — what is shown below is everything we have verified so far.
What the company says about itself
Web research — not auditedSurrozen is a biotechnology company founded by scientific leaders who uncovered the fundamental biology of Wnt signaling. The company develops multi-target antibody therapeutics to improve and restore sight in ophthalmic diseases with high unmet needs, focusing on conditions such as diabetic macular edema, wet age-related macular degeneration, and uveitic macular edema.
- Markets:
- Ophthalmology | Biotechnology
- Products:
- Wnt pathway modulating antibodies | Diabetic macular edema therapy | Wet age-related macular degeneration therapy | Uveitic macular edema therapy
Source: https://surrozen.com/ · captured Aug 26, 2026 · marketing claims are reported as claims, never merged into the filed figures above.
The deal it’s entering
Surrozen, Inc./DE is merging with Consonance-HFW Acquisition Corp. (CHFW) currently marked Closed (deSPAC).
| Headline equity value | — |
Structure per SEC accession(s) 0000950170-24-111493. How to read these numbers: headline vs effective valuation · what a definitive agreement commits
What exactly is being valued, and at what
Common questions
Is Surrozen, Inc./DE going public?
Surrozen, Inc./DE has an approved merger with the SPAC Consonance-HFW Acquisition Corp. (CHFW). Deal status: Closed (deSPAC).
Does Surrozen, Inc./DE have revenue?
The filings we've parsed don't state a usable revenue figure yet; this profile is updated as new documents land.
Educational content, not investment advice.